Sylvester Comprehensive Cancer Center

  • 20160793 - Barredo Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:
    RCemailImg Eva Pavicic
    RCphone +1 (305) 2437846

    IRB: 20160793

    		SDG: Pediatric Cancer
    Disease Site(s):

    Soft Tissue
    Sponsor: Moffitt Cancer Center

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
    Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201131 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20201131

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Stomach
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
    Eligibility Criteria - NCT04530981 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201132 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20201132

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: Tracon

    Enrolling Sites:

    Sylvester
    Title:

    A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
    Eligibility Criteria - NCT04480502 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201400 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:

    IRB: 20201400

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
    Eligibility Criteria - NCT02923778 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211131 - Jonczak Emily

  • Investigator:
    Emily Jonczak
    RCname Email

    		Coordinator:
    RCemailImg Sonali Kumar
    RCphone +1 (305) 2430279

    IRB: 20211131

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: ETCTN

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)
    Eligibility Criteria - NCT04595747 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
    Sponsor: CP

    Enrolling Sites:

    Sylvester
    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple
    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20191009

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx
    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers
    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC- 096 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:

    IRB: 20180804

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    AMC-096: A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
    Eligibility Criteria - NCT02799485 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • Anlotinib AL3818-US-004A - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20170072

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma
    Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"

  • 180114: TMZ-GIST - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone +1 (305) 2432441

    IRB: 20200974

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Colon,Esophagus,Small Intestine,Soft Tissue,Stomach
    Sponsor: University of California, San Diego

    Enrolling Sites:

    Sylvester
    Title:

    An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
    Eligibility Criteria - NCT03556384 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201368 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20201368

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester
    Title:

    ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)

  • 20210831 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20210831

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: ASTELLAS PHARMA US

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
    Eligibility Criteria - NCT04939701 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210970 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:

    IRB: 20210970

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: Foghorn Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    A phase 1, multicenter, open-label, dose escalation and expansion study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of intravenously administered fhd-609 in subjects with advanced synovial sarcoma
    Eligibility Criteria - NCT04965753 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211225 - Trent Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Ravipal Luthra

    IRB: 20211225

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bones and Joints
    Sponsor: Cogent Biosciences

    Enrolling Sites:

    Sylvester
    Title:

    (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS